SCHEDULE: ADAR1 Capital Discloses 6% Stake in OnKure Therapeutics

ADAR1 Capital Management and Daniel Schneeberger have reported a 6% beneficial ownership stake in OnKure Therapeutics, Inc. as of March 31, 2026.

Summary

• ADAR1 Capital Management, LLC, its general partner, and Daniel Schneeberger have filed a Schedule 13G indicating beneficial ownership of 2,434,941 shares of OnKure Therapeutics, Inc. Class A Common Stock.
• This holding represents 6.0% of the total 40,395,480 shares outstanding as of March 31, 2026.
• The shares are held across ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and other separately managed accounts.
• The filing confirms the acquisition was made in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine regulatory disclosure that reflects institutional interest but does not signal a change in company strategy or performance.

Positives

• Institutional investment interest from ADAR1 Capital Management suggests confidence in the company's long-term prospects.
• The reporting persons have explicitly stated the investment is passive, indicating no immediate intent to disrupt corporate governance.

Negatives

• Increased concentration of ownership by an investment firm can sometimes lead to future volatility if the firm decides to liquidate its position.

Risks

• The investment is subject to the general market risks associated with the biotechnology sector and the specific clinical development risks of OnKure Therapeutics.

Future Outlook

The filing does not provide specific forward-looking guidance regarding the issuer's business operations, as it is a standard disclosure of beneficial ownership.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard regulatory requirements for institutional investors crossing the 5% ownership threshold. This activity is common in the biotech sector, where institutional investors often build positions in anticipation of clinical trial milestones or strategic developments.

Comparison to Industry Standards

• The 6% stake is a typical position size for an investment firm acting as a passive institutional shareholder.
• The filing adheres to standard SEC reporting requirements for investment advisers under Rule 13d-1.

Stakeholder Impact

• Shareholders may view the entry of an institutional investor as a sign of market validation for the company's therapeutic pipeline.

Next Steps

• The reporting persons will be required to file amendments if there are material changes to their percentage of ownership.

Key Dates

Keywords

OnKure Therapeutics, Schedule 13G, ADAR1 Capital Management, Biotechnology, Institutional Ownership, Class A Common Stock